Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandrine Faivre

Showing results (1-10 of 139) with videos related to

Pageof 14
Sort By:
Expert Opinion on Investigational Drugs|October 17, 2008
Mechanism of action of rapalogues: the antiangiogenic hypothesisSandrine Faivre, Eric Raymond
Bulletin Du Cancer|July 10, 2003
[Non-AIDS-related malignancies: prognostic and treatment]Jean-Philippe Spano, Sandrine Faivre
Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2011
Novel molecular therapies in hepatocellular carcinomaSandrine Faivre, Mohamed Bouattour, Eric Raymond
Seminars in Oncology|August 8, 2006
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitorsSandrine Faivre, Siham Djelloul, Eric Raymond
Nature Reviews. Drug Discovery|August 3, 2006
Current development of mTOR inhibitors as anticancer agentsSandrine Faivre, Guido Kroemer, Eric Raymond
Journal of Hepatology|January 20, 2020
Molecular therapies for HCC: Looking outside the boxSandrine Faivre, Lorenza Rimassa, Richard S Finn
Oncology (Williston Park, N.Y.)|October 12, 2007
The role of integrins in colorectal cancerChristophe Le Tourneau, Sandrine Faivre, Eric Raymond
Current Opinion in Oncology|April 8, 2004
Optimal management of nasopharyngeal carcinomaSandrine Faivre, François Janot, Jean-Pierre Armand
Therapeutics and Clinical Risk Management|March 25, 2008
Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)Christophe Le Tourneau, Eric Raymond, Sandrine Faivre
Oncoimmunology|February 16, 2017
Novel TGF-<b>β</b> inhibitors ready for prime time in onco-immunologyArmand de Gramont, Sandrine Faivre, Eric Raymond
Pageof 14

Showing results (1-10 of 139) with videos related to

Sort By:
Pageof 14
Expert Opinion on Investigational Drugs|October 17, 2008
Mechanism of action of rapalogues: the antiangiogenic hypothesisSandrine Faivre, Eric Raymond
Bulletin Du Cancer|July 10, 2003
[Non-AIDS-related malignancies: prognostic and treatment]Jean-Philippe Spano, Sandrine Faivre
Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2011
Novel molecular therapies in hepatocellular carcinomaSandrine Faivre, Mohamed Bouattour, Eric Raymond
Seminars in Oncology|August 8, 2006
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitorsSandrine Faivre, Siham Djelloul, Eric Raymond
Nature Reviews. Drug Discovery|August 3, 2006
Current development of mTOR inhibitors as anticancer agentsSandrine Faivre, Guido Kroemer, Eric Raymond
Journal of Hepatology|January 20, 2020
Molecular therapies for HCC: Looking outside the boxSandrine Faivre, Lorenza Rimassa, Richard S Finn
Oncology (Williston Park, N.Y.)|October 12, 2007
The role of integrins in colorectal cancerChristophe Le Tourneau, Sandrine Faivre, Eric Raymond
Current Opinion in Oncology|April 8, 2004
Optimal management of nasopharyngeal carcinomaSandrine Faivre, François Janot, Jean-Pierre Armand
Therapeutics and Clinical Risk Management|March 25, 2008
Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)Christophe Le Tourneau, Eric Raymond, Sandrine Faivre
Oncoimmunology|February 16, 2017
Novel TGF-<b>β</b> inhibitors ready for prime time in onco-immunologyArmand de Gramont, Sandrine Faivre, Eric Raymond
Pageof 14